The PrepQuant platform combines nucleic acid extraction, concentration, and quantification into a single automated system for molecular workflows.
Invivoscribe has started commercial shipments of its PrepQuant System in North America. The platform, first introduced at the American Association for Cancer Research Annual Meeting in April 2026, has transitioned from development and validation to commercial deployment.
The system marks an expansion into laboratory instrumentation for the company, targeting sample preparation challenges in measurable residual disease (MRD) testing and other high-sensitivity molecular assays. According to Invivoscribe, the assay-agnostic instrument is designed to recover, concentrate, and quantify genomic DNA and cell-free DNA from larger blood, plasma, and bone marrow samples.
Addressing Workflow Bottlenecks in Molecular Testing
As clinical laboratories move toward higher-sensitivity MRD assays, sample preparation serves as a key factor in recovering rare disease-associated molecules. While increasing sample input volume can yield higher quantities of DNA for evaluation, the company notes that larger inputs present operational difficulties involving extraction efficiency, recovery, concentration, processing time, and consistency.
Many molecular laboratories currently use separate instruments and individual protocols to carry out extraction, concentration, and quantification. According to the company, transferring samples between disconnected platforms increases hands-on time, introduces risks of sample variability or manual error, and creates workflow bottlenecks as laboratory testing volumes increase. The design for the PrepQuant system was developed in response to operational challenges observed across LabPMM, the global clinical laboratory network operated by Invivoscribe.
Automated Multi-Step Processing
PrepQuant integrates extraction, concentration, and quantification into a single automated benchtop workflow. By consolidating these steps, the platform is intended to lower hands-on labor requirements, sample handling steps, operating costs, variability, and bench-space demands, according to Invivoscribe.
The system yields concentrated nucleic acids validated for use in blood, plasma, and bone marrow, with additional specimen types currently under development. The resulting material is compatible with downstream methodologies, including next-generation sequencing, capillary electrophoresis, quantitative polymerase chain reaction (PCR), and digital PCR.
“As precision oncology advances and MRD testing becomes mainstream, laboratories cannot focus on analytical sensitivity alone,” says Jeff Miller, CEO and chief scientific officer of Invivoscribe, in a release. “The ability to generate reliable molecular data begins upstream, with how the sample is processed and how effectively the available nucleic acid is recovered and consistently quantified. PrepQuant reflects our broader view that standardization across the entire testing continuum will be increasingly important as molecular MRD testing becomes integral both to monitoring disease and evaluating the effectiveness of new therapies.”
Commercial Availability
Initial shipments of the PrepQuant System are currently being delivered to clinical and research customers in North America. Invivoscribe expects commercial availability to expand to European laboratories in early 2027, while the company continues development on additional kits to support wider testing workflows.
